Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Mesenchymal Stem Cells, Advances and Applications
2.
Pharmacodynamic Assays Market Report
3.
Stem Cell Research Products
4.
Poly(ADP-ribose) polymerase (PARP) Research Products
5.
Advances in Biopharmaceutical Technology in India
6.
Directory of Top 60 Biopharmaceutical Manufacturers in China
7.
Directory of Top 60 Biopharmaceutical Manufacturers in India
8.
Outsourcing for contract manufacturing services 2008-2023
9.
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 Management Report
10.
Pfizer - Market Outlook for a Global Leader, 2008-2013
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Autoimmune and Inflammation Rheumatoid Arthritis Drug Pipeline Report
3.
The Global Rheumatoid Arthritis Market Forecasts to 2012
4.
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, March 2008
5.
Biostatistics course
6.
Worldwide Surgical Sealants, Glues and Wound Closure Market, 2007-2011
Introduction to Biopharma - Applications Course
Course Description:
This course describes computer-assisted drug design, introduces protein-based therapeutic agents, and describes the type of approaches used to treat immune-related diseases. This course describes the use of computer-based methods for designing new drugs and optimizing drug libraries and leads, introduces the design and use of protein based therapeutic agents, and introduces the immune system and immune related diseases.
Course Objectives:
> Define a drug pharmacophore and describe its key features.
> List three of the parameters involved in designing combinatorial libraries.
> Define which two parameters in drug optimization can be improved by design.
> Give two examples of drugs that have been synthesized by solid-phase combinatorial synthesis.
> Specify three major applications of protein design.
> Define what site-directed mutagenesis is and how it is utilized.
> Describe how peptidomimetics are designed.
> Explain how monoclonal antibodies are generated.
> Specify which parts of an antibody molecule are modified to humanize it.
> List three ways in which antibodies are utilized for therapeutic purposes.
> Specify the four disease groups that have an immune component involved in their pathology.
> List the cells and proteins involved in eliciting an immune response.
> Understand the different mechanisms by which the immune response responds to and eradicates infectious agents from the body.
> List four approaches for generating vaccines.
> Explain how the immune system can be manipulated to treat autoimmune diseases.
> List five common autoimmune diseases.
Course Outline:
Introduction
1. Course Information
2. Interface Tour
3. Course Overview
Computer-Assisted Drug Design (CADD)
4. Objectives
5. CADD Overview
6. Drug Pharmacophores
7. Library Design
8. Lead Optimization
9. Progress Check
Protein Therapeutics
10. Objectives
11. Protein Design
12. Protein Engineering
13. Antibody Structure
14. Therapeutic Peptides
15. Monoclonal Antibodies
16. Antibody Engineering
17. Antibody Therapeutics
18. Progress Check
Immunity and Disease
19. Objectives
20. Immunity and Disease
21. Immune Response
22. Vaccines
23. Vaccine Examples
24. Applications-Influenza
25. Applications-Autoimmune Disease
26. Progress Check
Conclusion
27. Summary
28. Final Assessment
Each Online Training Course or Professional Designation Program listed below comes complete with;
> 24 hour access to the course for 90 days,
> a printable PDF file including the notes to the course,
> a test used to measure your understanding of the material provided in the course, and
> a Certificate of Completion once you have passed a course, or;
> a Certificate of Professional Designation if you are enrolling in a Professional Designation program
Course Unit 3 of 3
Price: $105.00 / GBP54.60
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.